GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (ASX:ACW) » Definitions » ROE %

Actinogen Medical (ASX:ACW) ROE % : -182.11% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Actinogen Medical's annualized net income for the quarter that ended in Dec. 2023 was A$-23.11 Mil. Actinogen Medical's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was A$12.69 Mil. Therefore, Actinogen Medical's annualized ROE % for the quarter that ended in Dec. 2023 was -182.11%.

The historical rank and industry rank for Actinogen Medical's ROE % or its related term are showing as below:

ASX:ACW' s ROE % Range Over the Past 10 Years
Min: -107.61   Med: -51.48   Max: -27.62
Current: -107.61

During the past 13 years, Actinogen Medical's highest ROE % was -27.62%. The lowest was -107.61%. And the median was -51.48%.

ASX:ACW's ROE % is ranked worse than
78.31% of 1360 companies
in the Biotechnology industry
Industry Median: -44.355 vs ASX:ACW: -107.61

Actinogen Medical ROE % Historical Data

The historical data trend for Actinogen Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical ROE % Chart

Actinogen Medical Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.07 -40.15 -27.62 -48.46 -61.18

Actinogen Medical Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.15 -31.97 -78.69 -44.97 -182.11

Competitive Comparison of Actinogen Medical's ROE %

For the Biotechnology subindustry, Actinogen Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's ROE % falls into.



Actinogen Medical ROE % Calculation

Actinogen Medical's annualized ROE % for the fiscal year that ended in Jun. 2023 is calculated as

ROE %=Net Income (A: Jun. 2023 )/( (Total Stockholders Equity (A: Jun. 2022 )+Total Stockholders Equity (A: Jun. 2023 ))/ count )
=-10.752/( (21.74+13.407)/ 2 )
=-10.752/17.5735
=-61.18 %

Actinogen Medical's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-23.114/( (13.407+11.978)/ 2 )
=-23.114/12.6925
=-182.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Actinogen Medical  (ASX:ACW) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-23.114/12.6925
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-23.114 / 0)*(0 / 14.6865)*(14.6865 / 12.6925)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1571
=ROA %*Equity Multiplier
=N/A %*1.1571
=-182.11 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-23.114/12.6925
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-23.114 / -23.114) * (-23.114 / -25.124) * (-25.124 / 0) * (0 / 14.6865) * (14.6865 / 12.6925)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.92 * N/A % * 0 * 1.1571
=-182.11 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Actinogen Medical ROE % Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinogen Medical (ASX:ACW) Business Description

Traded in Other Exchanges
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Actinogen Medical (ASX:ACW) Headlines

From GuruFocus

Accuride Corporation: Earnings Report For Q2 2014

By Black Iguana Nitish 10-13-2014

Stocks That Are Making A Good Come Back

By reports.droy reports.droy 03-10-2015